Limited funding opportunity for faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver) involved in multi-therapeutic areas including: immuno-oncology, molecular oncology, and immunology & inflammation. Priority will be given to early stage therapeutics, novel disease targets, mechanisms and screening assays, new disease relevant animal models, biomarkers and technologies that improve drug discovery and development. A university-wide internal selection process is required.
Internal deadline: Monday, June 8, 2020 (see the internal submission guidelines below)
For the candidates selected:
Lisa Chen in the Industrial Contracts Office (ICO) will submit the top five project descriptions to Sanofi for review: June 19, 2020 (please note that Sanofi has granted Stanford a extension to the deadline in the RFA attached)
Sanofi will evaluate submitted projects, and if there is interest, they will reach back out to ICO to request a videoconference meeting with the PIs to discuss the project in more detail. Based on these meetings, final funding decisions will be made by July for an anticipated project start date by mid-to-late August.
NOTE: CE applicants must obtain an approved CE faculty PI waiver through their Research Process Manager (RPM) before the internal deadline.
NOTE: There should be NO confidential information disclosed in these pre-proposals.
Purpose/Amount of funding:
The Sanofi iAwards program is a multi-institutional academic partnership program designed to collaborate with academic investigators to quickly move promising early stage, disease relevant, innovative research towards the clinic. Through this program, Sanofi aims to fund innovative and translational research ideas that can contribute to our early stage pipeline and ultimately benefit patients. The selected proposals will receive:
• $125,000 research funding (including institutional indirect costs) for 12 months.
• Sanofi scientific expertise, dedicated project management support, and a scientific champion.
• In-kind resources such as reagents, tool compounds, etc. may be provided.
• Successful projects may be selected by Sanofi to receive additional funding for 2 to 3 years pursuant to a separate Sponsored Research Agreement (SRA). If your project progresses to a SRA, please note that there are non-standard intellectual property terms attached. Please contact Lisa Chen (email@example.com) in ICO for further details.
• Stanford faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver).
• Sanofi is requesting project descriptions from academic investigators in the participating institutions in multiple therapeutic areas including immuno-oncology, molecular oncology, and immunology & inflammation (see attached RFA for details).
• Proposals with third party collaborators other than those from partner institutions within the iAwards Program will not be considered. Proposals from HHMI investigators will not be considered.
AREAS OF INTEREST
Please see the attached RFP for details regarding Areas of Interest (immuno-oncology, molecular oncology, and immunology & inflammation).
Sanofi is seeking the following type of opportunities in the therapeutic areas provided below:
• Early stage compounds, small molecules or biologics targeting novel disease mechanisms
• Disease relevant targets with validated mechanism of action
• Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
• Novel therapeutic modalities
INTERNAL STANFORD SUBMISSION GUIDELINES:
By Monday, June 8, 2020, please submit your internal proposal via the Stanford Funding Opportunities portal HERE.
1) General Information
PI contact information: (name, title, department, address, email)
Indication and stage of development of project
Area of Interest
2) Brief non-confidential description of the project (limited to one page)
NOTE: There should be NO confidential information disclosed in these project descriptions.
Format: Arial 11 font, single-spaced, 1 inch margins
References and illustrations are not included in the page limit
3) PI Biosketch
4) Approved CE PI Waiver (if applicable)
The School of Medicine Awards committee, chaired by Dr. Peter Sarnow, will review the internal proposals and select the top five candidates to forward to the Industrial Contracts Office.
Includes funding opportunities specific to COVID-19
Limited submission programs, NIH resources, DoD CDMRP, internal funding opportunities, searchable funding databases.